Periostin in Bronchiolitis Obliterans Syndrome after Lung Transplant
International Journal of Molecular Sciences · 27.09.2024 · 25 (19) · 10423
DOI: 10.3390/ijms251910423 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 27.09.2024. Verfasst von Hye Ju Yeo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy, Pulmonary and Critical Care Medicine, Department of Internal Medicine, Transplant Research Center, Research Institute for Conver…. Hauptthemen laut MEDLINE: Bronchiolitis Obliterans, Lung Transplantation, Cell Adhesion Molecules, Biomarkers. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pusan National University Yangsan Hospital, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital.
Abstract (Originalsprache)
The utility of measuring serum periostin levels for predicting the occurrence of bronchiolitis obliterans syndrome (BOS) after lung transplantation remains underexplored. We analyzed differentially expressed genes (DEGs) between initially transplanted lung tissue and lung tissue with BOS from four patients. Periostin levels were assessed in 97 patients who had undergone lung transplantation 1 year post-transplantation and at the onset of BOS. The association between periostin levels and BOS, as well as their correlation with the decline in forced expiratory volume in one second (FEV1), was evaluated. Periostin levels in the BOS group were significantly higher than those in the control group (p < 0.001) and the stable group (p < 0.001). Periostin levels at the onset of BOS were significantly higher than those 1 year post-transplantation in the BOS group (p < 0.001). The serum periostin levels at the time of BOS diagnosis showed a positive correlation with the reduction in FEV1 (%) (r = 0.745, p < 0.001). The increase in the serum periostin levels at the time of BOS diagnosis compared with those 1 year post-transplantation was positively correlated with reduction in FEV1 (%) (r = 0.753, p < 0.001). Thus, serum periostin levels may serve as biomarkers for predicting a decline in lung function in patients with BOS after lung transplantation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Allergy, Pulmonary and Critical Care Medicine, Department of Internal Medicine, Transplant Research Center, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University…
- Department of Internal Medicine, School of Medicine, Pusan National University, Busan 43241, Republic of Korea.
- Department of research, Keimyung University Donsan Medical Center, Daegu 42601, Republic of Korea.
- Department of Anatomy, School of Medicine, Pusan National University, Yangsan 50612, Republic of Korea.
- Department of Biomedical Informatics, School of Medicine, Pusan National University, Yangsan 50612, Republic of Korea.
ORCID-Profile: Hye Ju Yeo, Yun Hak Kim, Woo Hyun Cho
Förderung
- Pusan National University Yangsan Hospital
- Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital
Zitieren
APA
Yeo, H. J., Kang, J., Kim, Y. H., & Cho, W. H. (2024). Periostin in Bronchiolitis Obliterans Syndrome after Lung Transplant. International Journal of Molecular Sciences, 25(19), 10423. https://doi.org/10.3390/ijms251910423
Vancouver
Yeo HJ, Kang J, Kim YH, Cho WH. Periostin in Bronchiolitis Obliterans Syndrome after Lung Transplant. International Journal of Molecular Sciences. 2024;25(19):10423. doi:10.3390/ijms251910423
BibTeX
@article{Yeo2024,
author = {Yeo, Hye Ju and Kang, Junho and Kim, Yun Hak and Cho, Woo Hyun},
title = {Periostin in Bronchiolitis Obliterans Syndrome after Lung Transplant},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {19},
pages = {10423},
doi = {10.3390/ijms251910423}
}
EUVIMED